Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of deucravacitinib in systemic lupus erythematosus
2022-502444-13-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of deucravacitinib in systemic lupus erythematosus (SLE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety: Adverse events and serious adverse events, Safety: Vital signs and 1 more. Started Oct 2023; status: completed.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-502444-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502444-13-00.